Brad Hively is Director at Oncology Institute, Inc. (TOI). They have made 10 open-market trades across 2 companies since 2022, most recently 2026-08-21.
CIK 0001891124
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
3 open-market purchases totalling $107K since 2024, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TOI | 710,829 | $3.6M |
| STLN | 411,976 | $2.6M |
| Total | $6.3M |
Shares reported on the most recent Form 4, priced at the 2026-08-24 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| STLN | SELL | 2026-08-21 | 2026-08-24 | $6.51 | $1.9M | -4.0% | +10.3% | — |
| TOI | SELL | 2025-12-15 | 2025-12-16 | $3.77 | $101K | -4.2% | -11.8% | -10.5% |
| TOI | SELL | 2025-08-19 | 2025-08-21 | $4.06 | $164K | -12.7% | -7.6% | -11.6% |
| TOI | SELL | 2025-06-03 | 2025-06-05 | $2.87 | $11.3M | -16.7% | -8.9% | +14.9% |
| TOI | BUY | 2025-03-26 | 2025-03-28 | $1.04 | $9K | +22.7% | +127.3% | +75.0% |
| TOI | BUY | 2025-03-26 | 2025-04-28 | $1.04 | $47K | +1.0% | +8.0% | +30.4% |
| TOI | BUY | 2024-11-26 | 2024-12-02 | $0.17 | $50K | +43.7% | +83.3% | +352.2% |
| TOI | SELL | 2023-11-17 | 2023-11-21 | $2.24 | $112K | -32.9% | -23.4% | -14.9% |
| TOI | SELL | 2023-11-13 | 2023-11-15 | $2.52 | $118K | -3.7% | -37.2% | -8.4% |
| TOI | SELL | 2022-11-15 | 2022-11-22 | $2.03 | $20K | -13.1% | -3.9% | -5.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.